Avadel Pharmaceuticals (AVDL) Retained Earnings (2016 - 2022)
Historic Retained Earnings for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$557.8 million.
- Avadel Pharmaceuticals' Retained Earnings fell 3109.96% to -$557.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$557.8 million, marking a year-over-year decrease of 3109.96%. This contributed to the annual value of -$447.8 million for FY2021, which is 1654.64% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Retained Earnings of -$557.8 million as of Q3 2022, which was down 3109.96% from -$537.6 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Retained Earnings peaked at -$274.9 million during Q1 2018, and registered a low of -$557.8 million during Q3 2022.
- Moreover, its 5-year median value for Retained Earnings was -$384.2 million (2020), whereas its average is -$393.5 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Retained Earnings skyrocketed by 987.56% in 2018, and later crashed by 3637.5% in 2019.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Retained Earnings stood at -$358.0 million in 2018, then decreased by 9.28% to -$391.2 million in 2019, then increased by 1.8% to -$384.2 million in 2020, then dropped by 16.55% to -$447.8 million in 2021, then dropped by 24.57% to -$557.8 million in 2022.
- Its Retained Earnings stands at -$557.8 million for Q3 2022, versus -$537.6 million for Q2 2022 and -$474.2 million for Q1 2022.